Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis - PubMed (original) (raw)
. 2011 Jan 13;117(2):500-9.
doi: 10.1182/blood-2010-05-284737. Epub 2010 Oct 18.
Affiliations
- PMID: 20956804
- DOI: 10.1182/blood-2010-05-284737
Free article
Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis
Makiko Hirai et al. Blood. 2011.
Free article
Abstract
Dendritic cells (DCs) play a pivotal role in the pathogenesis of inflammatory disorders, so suppressing the activity of DCs is instrumental in treating such diseases. In the present study, we show that a proteasome inhibitor, bortezomib, suppresses the survival and immunostimulatory function of human plasmacytoid DCs (pDCs) by targeting 2 critical points, intracellular trafficking of nucleic acid-sensingToll-like receptors (TLRs) and endoplasmic reticulum (ER) homeostasis. Among the immune cells in blood, pDCs were the most susceptible to the killing effect of bortezomib. This correlates with a decrease in the spliced form of a transcription factor XBP1, which rescues cells from apoptosis by maintaining ER homeostasis. Bortezomib suppressed the production of interferon-α and interleukin-6 by pDCs activated with a TLR9-stimulating CpG DNA and a TLR7-stimulating influenza virus, which appears to be partially independent of apoptosis. Bortezomib inhibited translocation of TLR9 from the ER to endolysosomes but not of an ER membrane protein, Unc93B1, that delivers TLR9 to endolysosomes. Thus, bortezomib suppresses the activity of pDCs by inhibiting intracellular trafficking of TLRs through disrupting the coordinated translocation of TLRs and Unc93B1 and by disturbing ER homeostasis. This study suggests that proteasome inhibitors may alleviate inflammatory disorders such as lupus and psoriasis that involve pDCs.
Comment in
- Protein stress? pDCs go Toll-free.
Dhodapkar MV. Dhodapkar MV. Blood. 2011 Jan 13;117(2):376-7. doi: 10.1182/blood-2010-11-315838. Blood. 2011. PMID: 21233320 No abstract available.
Similar articles
- Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Wissniowski TT, Meister S, Hahn EG, Kalden JR, Voll R, Ocker M. Wissniowski TT, et al. Int J Oncol. 2012 May;40(5):1581-9. doi: 10.3892/ijo.2012.1337. Epub 2012 Jan 18. Int J Oncol. 2012. PMID: 22266985 - Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells.
Dong H, Chen L, Chen X, Gu H, Gao G, Gao Y, Dong B. Dong H, et al. Leuk Lymphoma. 2009 Jun;50(6):974-84. doi: 10.1080/10428190902895780. Leuk Lymphoma. 2009. PMID: 19391038 - TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D, McConnell EJ, Dierlam L, Palamarchuk A, Lass A, Wójcik C. Nowis D, et al. Int J Cancer. 2007 Jul 15;121(2):431-41. doi: 10.1002/ijc.22695. Int J Cancer. 2007. PMID: 17373661 - Targeting endoplasmic reticulum signaling pathways in cancer.
Martinon F. Martinon F. Acta Oncol. 2012 Sep;51(7):822-30. doi: 10.3109/0284186X.2012.689113. Epub 2012 Jun 11. Acta Oncol. 2012. PMID: 22686473 Review. - Regulatory molecules required for nucleotide-sensing Toll-like receptors.
Saitoh S, Miyake K. Saitoh S, et al. Immunol Rev. 2009 Jan;227(1):32-43. doi: 10.1111/j.1600-065X.2008.00729.x. Immunol Rev. 2009. PMID: 19120473 Review.
Cited by
- Thiostrepton: multifaceted biological activities and its applications in treatment of inflammatory diseases.
Asikaer A, Sun C, Shen Y. Asikaer A, et al. Inflammopharmacology. 2024 Nov 2. doi: 10.1007/s10787-024-01587-9. Online ahead of print. Inflammopharmacology. 2024. PMID: 39487942 Review. - Multi-System-Level Analysis Reveals Differential Expression of Stress Response-Associated Genes in Inflammatory Solar Lentigo.
Jeong J, Lee W, Kim YA, Lee YJ, Kim S, Shin J, Choi Y, Kim J, Lee Y, Kim MS, Kwon SH. Jeong J, et al. Int J Mol Sci. 2024 Apr 3;25(7):3973. doi: 10.3390/ijms25073973. Int J Mol Sci. 2024. PMID: 38612783 Free PMC article. - Mitochondrial DNA Sensing Pathogen Recognition Receptors in Systemic Sclerosis Associated Interstitial Lung Disease: A Review.
Ghincea A, Woo S, Yu S, Pivarnik T, Fiorini V, Herzog EL, Ryu C. Ghincea A, et al. Curr Treatm Opt Rheumatol. 2023 Dec;9(4):204-220. doi: 10.1007/s40674-023-00211-1. Epub 2023 Aug 8. Curr Treatm Opt Rheumatol. 2023. PMID: 38230363 Free PMC article. - Clinical research progress of novel biologics for the treatment of lupus nephritis.
Cui W, Tian Y, Huang G, Zhang X, Li F, Liu X. Cui W, et al. Clin Exp Med. 2023 Dec;23(8):4153-4162. doi: 10.1007/s10238-023-01143-9. Epub 2023 Jul 22. Clin Exp Med. 2023. PMID: 37481481 Review. - Site-Specific Proteasome Inhibitors.
Kisselev AF. Kisselev AF. Biomolecules. 2021 Dec 31;12(1):54. doi: 10.3390/biom12010054. Biomolecules. 2021. PMID: 35053202 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources